BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
315.54
-4.87 (-1.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close320.41
Open322.30
Bid0.00 x 800
Ask0.00 x 900
Day's Range314.16 - 323.85
52 Week Range249.17 - 388.67
Volume1,565,706
Avg. Volume1,351,079
Market Cap63.563B
Beta (3Y Monthly)1.53
PE Ratio (TTM)22.40
EPS (TTM)14.08
Earnings DateOct 23, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est390.88
Trade prices are not sourced from all markets
  • GlobeNewswire7 minutes ago

    UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

    Biogen and UCB continue to further evaluate these data while assessing potential next steps. Dapirolizumab pegol is an investigational anti-CD40L pegylated Fab being developed in systemic lupus erythematosus (SLE) jointly by UCB and Biogen.

  • Biogen earnings: It’s all about upcoming Alzheimer’s disease results
    MarketWatch10 hours ago

    Biogen earnings: It’s all about upcoming Alzheimer’s disease results

    When drugmaker Biogen Inc. releases third-quarter earnings, scheduled for before the open on Tuesday, other major events for the company could well overshadow the financials. Chief among them is the company’s upcoming Alzheimer’s disease results, for the buzzed-about therapy BAN2401, which Biogen (BIIB) and partner Eisai (JP:4523) are set to present at an European conference this week. Call it financial déjà vu: The last time BAN2401 results were coming up, around Biogen’s second-quarter earnings, Wall Street analysts spent much of the company’s conference call asking about the trial.

  • Benzinga10 hours ago

    Biogen Q3 Earnings Outlook

    On Tuesday, Biogen (NASDAQ: BIIB ) will release its latest earnings report. Benzinga's outlook for Biogen is included in the following report. Earnings and Revenue Analysts covering Biogen modeled for ...

  • Analysts wary of Biogen's strategy as earnings, Alzheimer's data loom
    American City Business Journals13 hours ago

    Analysts wary of Biogen's strategy as earnings, Alzheimer's data loom

    "The path they're pursuing just seems to me to have too much risk," Baird analyst Brian Skorney told the Business Journal.

  • BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
    Zacks15 hours ago

    BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?

    We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.

  • Biogen on Deck as Biotechs Face Make-or-Break Earnings Season
    Bloomberg19 hours ago

    Biogen on Deck as Biotechs Face Make-or-Break Earnings Season

    (Bloomberg) -- Beaten-down biotech stocks have a lot riding on the third-quarter earnings season, which kicks off Tuesday when Biogen Inc. reports.

  • Benzingayesterday

    The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

    Biotech stocks are staging a rebound following the losses incurred in the week ended Oct. 12 amid catalysts that include the third-quarter earnings season and presentations at the European Society of Medical ...

  • Better Buy: Biogen Inc. vs. Amgen Inc.
    Motley Fool2 days ago

    Better Buy: Biogen Inc. vs. Amgen Inc.

    Which of these giant biotech stocks is the better pick right now?

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
    Zacks3 days ago

    Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?

    On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

  • Biogen: Analysts’ Recommendations on October 19
    Market Realist3 days ago

    Biogen: Analysts’ Recommendations on October 19

    Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

  • Biogen: Revenue Growth Is Expected in Q3
    Market Realist3 days ago

    Biogen: Revenue Growth Is Expected in Q3

    As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.

  • Analyzing Biogen before Its Third-Quarter Earnings
    Market Realist4 days ago

    Analyzing Biogen before Its Third-Quarter Earnings

    Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.

  • Alkermes Boasts Strong Portfolio and Impressive Pipeline
    Zacks4 days ago

    Alkermes Boasts Strong Portfolio and Impressive Pipeline

    Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

  • CNBC4 days ago

    Stocks making the biggest move premarket: PG, HON, F, VFC, HOG AMZN & more

    Procter & Gamble PG – The consumer products giant reported adjusted quarterly profit of $1.12 per share , exceeding estimates by 3 cents a share. Revenue also came in above Street forecasts and the company posted organic sales growth of 4 percent for its fiscal first quarter. Honeywell HON – Honeywell earned an adjusted $2.03 per share for the third quarter , 4 cents a share above estimates.

  • GlobeNewswire5 days ago

    Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

    EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27).

  • MIT researchers among winners of prestigious Breakthrough Prize
    American City Business Journals6 days ago

    MIT researchers among winners of prestigious Breakthrough Prize

    The honorees include several MIT researchers and the developers of a drug sold by Cambridge-based Biogen.

  • Reuters6 days ago

    Samsung launches third rival to AbbVie's Humira drug in EU

    LONDON (Reuters) - South Korea's Samsung Bioepis and its partner Biogen (BIIB.O) have launched a third rival to AbbVie's (ABBV.N) blockbuster medicine Humira in Europe, ramping up competition for a slice ...

  • Reuters6 days ago

    Samsung launches third rival to AbbVie's Humira drug in EU

    South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales. A fourth so-called biosimilar copy of Humira is expected soon from Mylan . The primary European patent on Humira expired on Oct. 16, opening the door to cheaper near-identical copies for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.

  • Business Wire6 days ago

    Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market

    CAMBRIDGE, Mass. & INCHEON, Korea-- -- IMRALDI TM , a biosimilar referencing HUMIRA ® i , is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe, following BENEPALI TM and FLIXABI TM Biogen and Samsung Bioepis were the first in Europe to receive approvals for biosimilars referencing the three most prescribed anti-TNF medicines in Europe. Biogen and ...

  • GlobeNewswire6 days ago

    IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union

    IMRALDITM is approved in the European Union for the same 14 complex autoimmune conditions as its reference product In 2017 Biogen became the first company in Europe with.

  • Gauging Analysts’ Views of Sarepta Stock in October
    Market Realist7 days ago

    Gauging Analysts’ Views of Sarepta Stock in October

    Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.

  • A Look at Sarepta Therapeutics’ Stock Performance
    Market Realist8 days ago

    A Look at Sarepta Therapeutics’ Stock Performance

    Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.

  • Key Collaborations Bode Well for Sarepta Therapeutics
    Market Realist8 days ago

    Key Collaborations Bode Well for Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.

  • Analyzing Sarepta’s Product Pipeline
    Market Realist8 days ago

    Analyzing Sarepta’s Product Pipeline

    Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.